CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last few shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire interview that I came away with a poor viewpoint of the company.

Irony of irony, my poor impression of the business enterprise has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology and linked intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) along with the very first brand new drug program approval ($five million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this single remedy as well as a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of my interest in this particular organization. Judging by way of the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Comments are Disabled